Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Type of study
Language
Year range
1.
Article in English | IMSEAR | ID: sea-178350

ABSTRACT

A subset of the tuberculous population has latent tuberculosis infection (LTBI). It is a condition wherein the affected individual is infected with Mycobacterium tuberculosis, but does not have any signs or symptoms of tuberculosis nor is he infectious to others. Risk of progression to active tuberculous infection is influenced by co-morbidities like HIV, diabetes, malignancy requiring chemotherapy, infants and children in close contact with susceptible individuals, and healthcare workers. Early diagnosis of LTBI is paramount. In addition to tuberculin test, Interferon gamma release assay (IGRA) is the new diagnostic modality that can be used for this purpose. Quantiferon-TB Gold In-Tube (QFTGIT) and T-SPOT TB are the two currently available IGRAs, of which the latter is slightly more preferred. More recently, TB PCR (Polymerase Chain Reaction) has aided accurate and early diagnosis of all forms of TB. While treating LTBI, it is observed that Isoniazid (INH) has stood the test of time and still prevails as the treatment of choice for active infection and for LTBI. Of course, adverse effects of INH and need for regular laboratory monitoring persist. Recently, moxifloxacin has been used as a substitute for INH. Newer drugs like rifapentine, nitromidazopyran, metronidazole and nitrofurans have all been tried with variable success and several clinical limitations, depending on comorbid conditions. India’s burden of extensive prevalence of TB is compounded by paucity of data on the same. The World Health Organization has estimated a mortality of 36 million by 2020 due to TB. This projection should encourage aggressive research into this entity.

2.
Article in English | IMSEAR | ID: sea-153912

ABSTRACT

Background: The benzodiazepine, Midazolam, has been used medication given for sedation in tympanoplasty and mastoidectomy because of a number of beneficial effects. However, Dexmedetomidine is a highly selective α2-adrenoceptor agonist is emerging as preferred choice now a day. The aim of the study is to compare hemodynamic stability and sedation under Dexmedetomidine vs Midazolam during tympanoplasty and modified radical mastoidectomy done under local anaesthesia. Methods: After obtaining ethics clearance from institution and written informed consent from patients, 50 patients of age group 15 to 50 years of ASA grade i & ii were selected and divided in to two groups: Group D: Inj. Dexmedetomidine 1µg/kg over 15min, followed by 0.5µg/kg/hr (n= 25). Group M: Inj. Midazolam 0.05 mg/kg i.v. slowly, followed by 0.01mg/kg/hr (n= 25). Arterial blood pressure, heart rate and sedation level were monitored. The surgeons and patients were asked to rate their satisfaction, using the Likert scale. Results: Sedation score difference between group Dand group M was not statistically significant. There was no statistically significant difference found in diastolic blood pressure of both the groups. There was a significant reduction in heart rate in group D as compared to group M. Surgeon’s satisfaction score and patient’s satisfaction score both were high in group D compare to group M. Conclusions: For monitored anaesthesia care in ENT surgeries performed under local anaesthesia, inj. Dexmedetomidine could be a better alternative over inj. Midazolam.

SELECTION OF CITATIONS
SEARCH DETAIL